Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

reneopharma.com

Founded Year

2014

Stage

IPO | IPO

Total Raised

$145M

Date of IPO

4/9/2021

Market Cap

0.07B

Stock Price

3.01

About Reneo Pharmaceuticals

Reneo Pharmaceuticals (NASDAQ: RPHM) is a biotechnology company focused on developing treatments for orphan diseases.

Reneo Pharmaceuticals Headquarters Location

12230 El Camino Real Suite 230

San Diego, California, 92130,

United States

858-283-0280

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Reneo Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Reneo Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Reneo Pharmaceuticals Patents

Reneo Pharmaceuticals has filed 5 patents.

The 3 most popular patent topics include:

  • Small nuclear RNA
  • Transcription factors
  • Carboxylic acids
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/20/2021

3/8/2022

Fluoroarenes, Small nuclear RNA, Transcription factors, Designer drugs, Carboxylic acids

Grant

Application Date

7/20/2021

Grant Date

3/8/2022

Title

Related Topics

Fluoroarenes, Small nuclear RNA, Transcription factors, Designer drugs, Carboxylic acids

Status

Grant

Latest Reneo Pharmaceuticals News

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Sep 6, 2022

San Diego, California, UNITED STATES IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the following conferences in September, as detailed below: Baird Global Healthcare Conference (September 13-14, 2022) Location: InterContinental New York Barclay, Morgan Suite, Mezzanine Level Presentation: Tuesday, September 13, 2022, 10:50AM ET (Session IV) 11th Annual SVB Securities Healthcare Summit (September 21-23, 2022) Location: Rosewood Miramar Beach, Montecito, California Ladenburg Thalmann Annual Healthcare Conference (September 29, 2022) Location: Sofitel Hotel, New York, NY, Track 3 – Montmarte Fireside Chat: Thursday, September 29, 2022, 11:00 AM ET Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website, under Events and Presentations. About Reneo Pharmaceuticals Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. For additional information, please see reneopharma.com. Contacts:

Reneo Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Reneo Pharmaceuticals Rank

  • When was Reneo Pharmaceuticals founded?

    Reneo Pharmaceuticals was founded in 2014.

  • Where is Reneo Pharmaceuticals's headquarters?

    Reneo Pharmaceuticals's headquarters is located at 12230 El Camino Real, San Diego.

  • What is Reneo Pharmaceuticals's latest funding round?

    Reneo Pharmaceuticals's latest funding round is IPO.

  • How much did Reneo Pharmaceuticals raise?

    Reneo Pharmaceuticals raised a total of $145M.

  • Who are the investors of Reneo Pharmaceuticals?

    Investors of Reneo Pharmaceuticals include Pappas Ventures, New Enterprise Associates, RiverVest Venture Partners, Lundbeckfond Ventures, Novo Ventures and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.